HCW Biologics Enters Material Definitive Agreement

TL;DR

HCW Biologics just signed a big deal, details TBD.

AI Summary

HCW Biologics Inc. announced on July 18, 2024, that it entered into a material definitive agreement. The filing does not disclose specific details of the agreement, such as the counterparty or financial terms, but indicates it is a significant event for the company.

Why It Matters

This filing signals a significant development for HCW Biologics, potentially impacting its strategic direction, partnerships, or financial standing.

Risk Assessment

Risk Level: medium — The lack of specific details in the filing creates uncertainty about the nature and implications of the agreement, warranting a medium risk assessment.

Key Players & Entities

• HCW Biologics Inc. (company) — Registrant
• July 18, 2024 (date) — Date of Report
• Delaware (jurisdiction) — State of Incorporation
• 2929 N. Commerce Parkway (address) — Principal Executive Offices
• Miramar, Florida (location) — Principal Executive Offices City and State

FAQ

Key Financial Figures

• $0.0001 — ch registered Common Stock, par value $0.0001 per share HCWB The Nasdaq Stock Mar

Filing Documents

• hcwb-20240718.htm (8-K) — 41KB
• 0000950170-24-084433.txt ( ) — 152KB
• hcwb-20240718.xsd (EX-101.SCH) — 24KB
• hcwb-20240718_htm.xml (XML) — 5KB

01 Entry into a Material Definitive Agreement

Item 1.01 Entry into a Material Definitive Agreement. As of July 13, 2024, HCW Biologics Inc. (the "Company") and Dr. Hing C. Wong, the Company's Founder and CEO, entered into a confidential Settlement Agreement and Release (the "Settlement Agreement") with Altor BioScience, LLC ("Altor"), NantCell, Inc. ("NantCell"), and ImmunityBio, Inc. (the parent of Altor and NantCell, together with Altor and NantCell, "ImmunityBio"), to resolve the previously disclosed arbitration before JAMS brought by Altor and NantCell, alleging breach of contract and fiduciary duty, among other claims, against Dr. Wong and misappropriation of trade secrets, inducement of breach of contract and inducement of breach of fiduciary duty, among other claims, against the Company (the "Arbitration"). The parties entered into the Settlement Agreement to avoid the costs, disruption and distraction of further litigation. The detailed terms of the Settlement Agreement are confidential but are summarized below. Under the terms of the Settlement Agreement, no party will make monetary payments to any other party or person and each party will bear its own expenses. None of the parties to the Settlement Agreement admitted any fault, liability or wrongdoing. The terms of the Settlement Agreement include, among other things, mutual releases and the Company's agreement to transfer to ImmunityBio certain rights with respect to select molecules developed using the Company's TOBI TM discovery development platform with respect to certain cancer indications and certain other intellectual property and intellectual property rights. The Settlement Agreement obligates the parties thereto to take various post-execution steps, which are anticipated to include dismissing the Arbitration and the pending action in the Delaware Court of Chancery between Altor and the Company. The foregoing summary of the terms of the Settlement Agreement does not purport to be complete.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. HCW BIOLOGICS INC. Date: July 18, 2024 By: /s/ Hing C. Wong Hing C. Wong, Founder and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR